A study led by Dr William Turpin (University of Toronto, ON, Canada) and colleagues aimed to identify fibre subtypes associated with CD risk and to analyse their relationship with inflammation, barrier function, and the gut microbiota [1]. In total, 3,314 healthy first-degree relatives of patients with CD were followed prospectively. The investigators quantified the intake of various fibre subtypes, including pectin, β-glucan, inulin, fructooligosaccharides, and arabinoxylan, using dietary questionnaires. They also assessed intestinal permeability, subclinical gut inflammation, and faecal microbiome composition.
Inulin and β-glucan intake were significantly associated with a reduced risk of developing CD (see Figure). These fibre subtypes, along with fructooligosaccharides, were also linked to improved intestinal barrier integrity, as measured by the lactulose-to-mannitol ratio (≤ 0.025). Although none of the fibre types were associated with lower faecal calprotectin levels, inulin, β-glucan, and fructooligosaccharides were correlated with reduced C-reactive protein (CRP) levels. “In addition, we performed a multi-omics analysis and found that inulin and β-glucan were associated with lower concentrations of proteins previously linked to inflammation and barrier-disruption,” explained Dr Turpin.
Figure: Fibre subtype and risk of CD onset [1]

FDRs, first-degree relatives; CD, Crohn’s disease; FOS, fructooligosaccharides; AX, arabinoxylan.
Finally, the investigators reported that the bacterial genera Colidextribacter and Romboutsia appear to modulate the protective association between inulin and β-glucan intake and the risk of developing CD.
“Higher intake of inulin and β-glucan was associated with a reduced risk of CD onset,” concluded Dr Turpin. “These findings suggest that such fibres may beneficially influence barrier function, inflammation, and microbiome composition. Targeted dietary interventions based on these insights could help to prevent the onset of CD.”
- Turpin W, et al. Fermentable fiber intake and reduced Crohn’s disease risk: insights from the GEM prospective cohort. OP066, IBD: What about the environment? UEG Week, 4-7 October 2025, Berlin, Germany.
Copyright ©2025 Medicom Medical Publishers
Posted on
Previous Article
« Prospective insight into dietary patterns and relapse risk in IBD Next Article
Risk-stratified screening for CRC is more effective at the same spending rate »
« Prospective insight into dietary patterns and relapse risk in IBD Next Article
Risk-stratified screening for CRC is more effective at the same spending rate »
Table of Contents: UEGW 2025
Featured articles
Mufemilast advances to phase 3 following positive phase 2 results in UC
Malignancies and Related Topics
Early detection of pancreatic cancer with an AI tool may save lives
Endoscopic approach preferred over surgery in gastric outlet syndrome
Reducing TME burden with a risk-stratified approach in early rectal cancer
PuraStat is effective and safe in real-world radiation proctopathy
Extended surveillance intervals after colorectal ESD may be safe and feasible
A machine learning model to improve bowel preparation quality monitoring
Can vedolizumab simplify the management of checkpoint inhibitor-induced enterocolitis?
Risk-stratified screening for CRC is more effective at the same spending rate
Highlights in Hepatology
Sugar-sweetened and non-sugar–sweetened beverages linked to MASLD risk
GLISTEN: Linerixibat meets primary endpoint in PBC-associated cholestatic pruritus
Even limited alcohol consumption is linked to increased MASLD risk
GLP-1 agonists in MASH: State-of-affairs
Diverse Top Research From UEG Week
Rabeprazole may be the preferred high-dose PPI in severe eGERD
Promising signs from a novel Helicobacter Pylori vaccine
Improving prevention and sustainability go hand-in-hand in IBD care
TRIASSIC: ESD superior to TAMIS for resection of non-pedunculated rectal lesions
Promising novel treatment option for functional dyspepsia
Latest Advancements in IBD
Intake of specific fibre subtypes linked to reduced risk of CD onset
Prospective insight into dietary patterns and relapse risk in IBD
Mufemilast advances to phase 3 following positive phase 2 results in UC
High-dose obefazimod is efficacious in UC regardless of prior therapy exposure
Can SIK3 inhibition become the Holy Grail for autoimmune diseases?
Relapse rate and risk factors after anti-TNF withdrawal in UC
TURN2: Well-prepared FMT shows efficacy in UC
Different outcomes of AI-read versus human-read endoscopies in the TITRATE study
Treatment efficacy of 7 therapies in perianal fistulising CD
ASTRO: Subcutaneous guselkumab maintains efficacy in UC through 2 years of follow-up
ANTHEM-UC: Oral IL-23 inhibitor delivers encouraging phase 2 data
Related Articles
December 24, 2020
PPI therapy may render infliximab less effective in IBD patients
April 14, 2020
Pipeline of IBD drugs
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com
